Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
3.120
-0.120 (-3.70%)
May 13, 2025, 4:00 PM - Market closed
Cyclerion Therapeutics Employees
Cyclerion Therapeutics had 1 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$2,081,000
Profits / Employee
-$2,944,000
Market Cap
10.02M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CYCN News
- 5 months ago - Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewsWire
- 10 months ago - Regina Graul, Ph.D., Promoted to Chief Executive Officer - GlobeNewsWire
- 1 year ago - Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewsWire
- 1 year ago - Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewsWire
- 1 year ago - Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets - GlobeNewsWire
- 2 years ago - Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 2 years ago - Cyclerion Announces Reverse Stock Split - GlobeNewsWire
- 2 years ago - Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewsWire